| 1. |
Naeem S, Wang F, Mubarak R, et al. Mapping the Global distribution, risk factors, and temporal trends of COPD incidence and mortality (1990-2021): ecological analysis[J]. BMC Med, 2025, 23(1): 210.
|
| 2. |
Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation[J]. Int J Chron Obstruct Pulmon Dis, 2011, 6: 413-421.
|
| 3. |
Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2017, 15(1): 55-63.
|
| 4. |
Corrêa RO, Castro PR, Moser R, et al. Butyrate: Connecting the gut-lung axis to the management of pulmonary disorders[J]. Front Nutr, 2022, 9: 1011732.
|
| 5. |
Verma A, Bhagchandani T, Rai A, et al. Short-chain fatty acid (SCFA) as a connecting link between microbiota and gut-lung axis-a potential therapeutic intervention to improve lung health[J]. ACS Omega, 2024, 9(13): 14648-14671.
|
| 6. |
Otake S, Chubachi S, Miyamoto J, et al. Impact of smoking on gut microbiota and short-chain fatty acids in human and mice: implications for COPD[J]. Mucosal Immunol, 2025, 18(2): 353-365.
|
| 7. |
Ni FX, Wang HX, Hu J, et al. The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies[J]. Front Immunol, 2026, 17: 1733726.
|
| 8. |
Li N, Dai Z, Wang Z, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease[J]. Respir Res, 2021, 22(1): 274.
|
| 9. |
Zhu H, Wu C, Wu H, et al. The gut microbiota-SCFA-inflammation axis in patients with AECOPD[J]. PLoS One, 2025, 20(1): e0312606.
|
| 10. |
Tanabe N, Matsumoto H, Morimoto C, et al. Sputum short-chain fatty acids, microbiome, inflammation, and mucus plugging in obstructive airway disease[J]. J Allergy Clin Immunol, 2025, 155(5): 1675-1680.
|
| 11. |
Aghapour M, Ubags ND, Bruder D, et al. Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD[J]. Eur Respir Rev, 2022, 31(163).
|
| 12. |
Richards LB, Li M, Folkerts G, et al. Butyrate and propionate restore the cytokine and house dust mite compromised barrier function of human bronchial airway epithelial cells[J]. Int J Mol Sci, 2020, 22(1): 65.
|
| 13. |
Liu J, Hong W, Sun Z, et al. The gut-lung axis: effects and mechanisms of gut microbiota on pulmonary diseases[J]. Front Immunol, 2025, 16: 1693964.
|
| 14. |
Li X, Jing Z, Li S, et al. Immunomodulatory effects of short-chain fatty acids in chronic obstructive pulmonary disease: rebalancing Th17/Treg axis and enhancing epithelial repair[J]. Cytotechnology, 2025, 77(6): 188.
|
| 15. |
Gao Y, Wang K, Lin Z, et al. The emerging roles of microbiome and short-chain fatty acids in the pathogenesis of bronchopulmonary dysplasia[J]. Front Cell Infect Microbiol, 2024, 14: 1434687.
|
| 16. |
Zhu J, Yang L, Fang Z, et al. Xin-Jia-Tong-Xie-Yao-Fang restores the intestinal barrier to alleviate irritable bowel syndrome via microbial butyrate mediated PI3K/Akt pathway suppression[J]. Microb Pathog, 2026, 213: 108344.
|
| 17. |
Yu X, Yu X, Wang Y, et al. Respiratory diseases and the gut microbiota: an updated review[J]. Front Cell Infect Microbiol, 2025, 15: 1629005.
|
| 18. |
Zhang D, Jian Y P, Zhang YN, et al. Short-chain fatty acids in diseases[J]. Cell Commun Signal, 2023, 21(1): 212.
|
| 19. |
Chen H, Xu Y, Qiu J, et al. Differential regulatory mechanisms of gut-derived SCFAs (acetate, propionate, butyrate) on the pulmonary TLR2 signaling pathway and their roles in the inflammatory balance of bacterial pneumonia[J]. Eur J Med Res, 2026, 31(1): 249.
|
| 20. |
Zhao Z, Tong Y, Kang Y, et al. Sodium butyrate (SB) ameliorated inflammation of COPD induced by cigarette smoke through activating the GPR43 to inhibit NF-κB/MAPKs signaling pathways[J]. Mol Immunol, 2023, 163: 224-34.
|
| 21. |
Mao J, Li Y, Bian Q, et al. The Bufei Jianpi formula improves mucosal immune function by remodeling gut microbiota through the SCFAs/GPR43/NLRP3 pathway in chronic obstructive pulmonary disease rats[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17: 1285-1298.
|
| 22. |
Guo W, Gong Q, Zong X, et al. GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal axis[J]. Exp Hematol Oncol, 2023, 12(1): 15.
|
| 23. |
Liu Z, Fan Q, Sun R, et al. Qingfei Tongluo Jiedu formula regulates M2 macrophage polarization via the butyric Acid-GPR109A-MAPK pathway for the treatment of mycoplasma pneumoniae pneumonia[J]. Pharmaceuticals (Basel), 2026, 19(2): 212.
|
| 24. |
Korsten S, Peracic L, van Groeningen LMB, et al. Butyrate prevents induction of CXCL10 and non-canonical IRF9 expression by activated human intestinal epithelial cells via HDAC inhibition[J]. Int J Mol Sci, 2022, 23(7): 3980.
|
| 25. |
Wang J, Zhao Q, Zhang S, et al. Microbial short chain fatty acids: effective histone deacetylase inhibitors in immune regulation (Review)[J]. Int J Mol Med, 2026, 57(1): 16.
|
| 26. |
Jiang M, Wang J, Li Z, et al. Dietary fiber-derived microbial butyrate suppresses ILC2-dependent airway inflammation in COPD[J]. Mediators Inflamm, 2024, 2024: 6263447.
|
| 27. |
Yasuda H, Takishita Y, Morita A, et al. Sodium acetate enhances neutrophil extracellular trap formation via histone acetylation pathway in neutrophil-like HL-60 cells[J]. Int J Mol Sci, 2024, 25(16): 8757.
|
| 28. |
Zou F, Qiu Y, Huang Y, et al. Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function[J]. Cell Death Dis, 2021, 12(6): 582.
|
| 29. |
Jiang M, Jiang Q, Wu H, et al. Butyrate ameliorates lung inflammation in chronic obstructive pulmonary disease in association with the regulation of histone lactylation: a mechanistic study[J]. Life Sci, 2026, 386: 124170.
|
| 30. |
Ryan E M, Sadiku P, Coelho P, et al. NRF2 activation reprograms defects in oxidative metabolism to restore macrophage function in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2023, 207(8): 998-1011.
|
| 31. |
González-Bosch C, Boorman E, Zunszain PA, et al. Short-chain fatty acids as modulators of redox signaling in health and disease[J]. Redox Biol, 2021, 47: 102165.
|
| 32. |
張璐, 丁煥章, 許浩燃, 等. 參芪補中方通過激活AMPK/SIRT1/PGC-1α改善COPD肺脾氣虛證大鼠線粒體功能障礙[J]. 南方醫科大學學報, 2025, 45(5): 969-976.
|
| 33. |
Tang MY, Xie H, Tao JT, et al. Pathophysiological relevance and therapeutic outlook of GPR43 in atherosclerosis[J]. Biochem Cell Biol, 2024, 102(6): 418-429.
|
| 34. |
Pan M, Zhou X. Airway remodeling in chronic obstructive pulmonary disease: characteristics and opportunities[J]. Front Med (Lausanne), 2025, 12: 1556868.
|
| 35. |
Rizi RR, Hamedani H, Cereda M. In Chronic obstructive pulmonary disease progression, is it airway narrowing or airway loss?[J]. Am J Respir Crit Care Med, 2021, 203(2): 154-155.
|
| 36. |
Lee HY, Nam S, Kim MJ, et al. Butyrate prevents TGF-β1-induced alveolar myofibroblast differentiation and modulates energy metabolism[J]. Metabolites, 2021, 11(5): 258.
|
| 37. |
Wu Y, Li Y, Luo Y, et al. Gut microbiome and metabolites: the potential key roles in pulmonary fibrosis[J]. Front Microbiol, 2022, 13: 943791.
|
| 38. |
Kirschner SK, Engelen M P, Haas P, et al. Short-chain fatty acid kinetics and concentrations are higher after inulin supplementation in young and older adults: a randomized trial[J]. Am J Clin Nutr, 2025, 121(6): 1224-1235.
|
| 39. |
Kirschner SK, Ghane P, Park JK, et al. Short-chain fatty acid production in accessible and inaccessible body pools as assessed by novel stable tracer pulse approach is reduced by aging independent of presence of COPD[J]. Metabolism, 2023, 141: 155399.
|
| 40. |
Liu X, Hu Z, Zhang Q. Associations between dietary index for gut microbiota with COPD prevalence and all-cause mortality: insights from the 1999-2018 NHANES data[J]. BMC Pulm Med, 2025, 25(1): 417.
|
| 41. |
Zuo S, Li H, Ma L, et al. Association between the dietary index for gut microbiota (DI-GM) and all-cause mortality in older adults with COPD: evidence from the NHANES[J]. Medicine (Baltimore), 2026, 105(6): e47617.
|
